Hudson Bay Capital Management LP Morpho Sys Ag Transaction History

Hudson Bay Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.72 - $8.6 $957,600 - $1.23 Million	-142,500 Reduced 23.85%	455,000 $3.06 Million
Q2 2023 Aug 14, 2023	SELL	$3.95 - $7.74 $1.04 Million - $2.03 Million	-262,500 Reduced 30.52%	597,500 $4.46 Million
Q1 2023 May 16, 2023	BUY	$3.56 - $5.22 $617,432 - $905,335	173,436 Added 25.26%	860,000 $3.41 Million
Q1 2023 May 15, 2023	SELL	$3.56 - $5.22 $795,432 - $1.17 Million	-223,436 Reduced 24.55%	686,564 $2.72 Million
Q4 2022 Feb 14, 2023	BUY	$3.21 - $5.74 $224,700 - $401,800	70,000 Added 8.33%	910,000 $3.26 Million
Q3 2022 Nov 14, 2022	SELL	$4.14 - $22.13 $124,199 - $663,900	-30,000 Reduced 3.45%	840,000 $4.23 Million
Q2 2022 Aug 12, 2022	BUY	$4.51 - $7.39 $1.46 Million - $2.39 Million	323,700 Added 59.25%	870,000 $4.21 Million
Q1 2022 May 16, 2022	BUY	$5.87 - $9.73 $858,781 - $1.42 Million	146,300 Added 36.58%	546,300 $3.7 Million
Q4 2021 Feb 14, 2022	BUY	$9.08 - $12.45 $1.68 Million - $2.3 Million	185,015 Added 86.06%	400,000 $3.77 Million
Q3 2021 Nov 15, 2021	BUY	$11.76 - $19.51 $2.53 Million - $4.19 Million	214,985 New	214,985 $2.53 Million

1.8M

14.7K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.